Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

BACKGROUND: N8‐GP is an extended half‐life recombinant factor VIII developed for prophylaxis and treatment of bleeds in patients with hemophilia A. OBJECTIVE: To assess pharmacokinetic (PK) characteristics of N8‐GP in previously treated patients with severe hemophilia A, model the time spent at hemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdary, Pratima, Carcao, Manuel, Holme, Pål A., Jiménez‐Yuste, Victor, Lentz, Steven R., Møss, Judi, Poulsen, Lone H., Shen, Chunduo, Tosetto, Alberto, Wheeler, Allison, Santagostino, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Online‐only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611478/
https://www.ncbi.nlm.nih.gov/pubmed/31294338
http://dx.doi.org/10.1002/rth2.12220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611478/
https://www.ncbi.nlm.nih.gov/pubmed/31294338
http://dx.doi.org/10.1002/rth2.12220

Ejemplares similares